Cargando…
EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma
BACKGROUND: Despite the remarkable breakthroughs achieved in the management of metastatic melanoma using immunotherapy and targeted therapies, long‐term clinical efficacy is often compromised due to dose‐limiting toxicity and innate or acquired resistance. Therefore, it is of vital importance to fur...
Autores principales: | Deng, Guangtong, Zeng, Furong, He, Yi, Meng, Yu, Sun, Huiyan, Su, Juan, Zhao, Shuang, Cheng, Yan, Chen, Xiang, Yin, Mingzhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858631/ https://www.ncbi.nlm.nih.gov/pubmed/35184394 http://dx.doi.org/10.1002/ctm2.722 |
Ejemplares similares
-
BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway
por: Deng, Guangtong, et al.
Publicado: (2020) -
BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression
por: Zeng, Furong, et al.
Publicado: (2023) -
Synergise or perish
por: Grover, Harpreet Singh
Publicado: (2021) -
Nomogram based on autophagy related genes for predicting the survival in melanoma
por: Deng, Guangtong, et al.
Publicado: (2021) -
The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy
por: Li, Yayun, et al.
Publicado: (2022)